Livogrid 1000 Tablet contains Levetiracetam 1000 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Livogrid 1000 is typically prescribed as adjunctive therapy but may also be used as monotherapy depending on clinical evaluation. The tablet is administered orally, with dosing individualized based on patient response, age, and renal function. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings; however, it is generally well tolerated. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Livogrid 1000 should be used under strict medical supervision, with regular monitoring for efficacy and side effects. It is contraindicated in individuals with known hypersensitivity to Levetiracetam or any of its excipients. Patients are advised not to discontinue therapy abruptly to avoid seizure exacerbation. Livogrid 1000 offers a valuable option in epilepsy management, contributing to improved seizure control and enhanced quality of life.